The World Health Organisation (WHO) has strongly warned against the use of the antiviral drug, Remdesivir, for treatment of COVID-19 patients in the hospital.
At a forum on Thursday, a panel of experts from WHO said there is currently no evidence that the drug improves the survival of COVID-19 patients.
The WHO Guideline Development Group (GDG) based its recommendation on new evidence review comparing the effects of several drug treatments on more than 7,000 patients hospitalised with COVID-19 in four international randomised trials.
“The evidence did not prove that Remdesivir had no benefit at all, rather that there was no evidence – given currently available data – that it did improve important patient outcomes,” the panel added.
Trial by researchers using four drugs including Remdesivir in the hospital treatment of COVID-19 had last month found that the repurposed medicines have little to no effect on the length of time patients spend in the hospital or their survival.
- 122 fresh COVID-19 cases take Nigeria’s total to 67,960. Deaths, recoveries updated - December 3, 2020
- ‘Put 2023 ambition on hold, find solutions to Nigeria’s security challenges,’ Saraki tells politicians - December 3, 2020
- With N9.4bn bribes in two years, judiciary tops ICPC corruption index - December 2, 2020